February 29, 2024

Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024

February 28, 2024

Moderna to Present at Upcoming Investor Conferences in March 2024

February 22, 2024

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates

December 15, 2023

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine

December 14, 2023

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years

December 12, 2023

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025

December 07, 2023

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event

November 14, 2023

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023

November 08, 2023

Moderna to Present at Upcoming Conferences in November 2023

November 08, 2023

Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event

November 07, 2023

Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year

November 02, 2023

Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates

October 30, 2023

CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission

October 26, 2023

Moderna Named a Top Employer by Science for Ninth Consecutive Year

October 24, 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19

October 24, 2023

Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

October 19, 2023

Moderna to Host Second Digital Investor Event on November 8th, 2023

October 12, 2023

Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023

October 04, 2023

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19

September 29, 2023

Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation

September 14, 2023

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union

September 13, 2023

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

September 11, 2023

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine

September 11, 2023

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

September 08, 2023

Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

September 06, 2023

Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference

September 06, 2023

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86

August 30, 2023

Moderna to Host Investor Event - R&D Day and Business Updates

August 17, 2023

Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

August 14, 2023

UMass Chan Medical School announces enrollment in study to examine impact of cytomegalovirus (CMV) transmission in early education settings

August 03, 2023

Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates

July 13, 2023

Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

July 05, 2023

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345

July 03, 2023

Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

June 29, 2023

MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE

June 22, 2023

Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine

June 05, 2023

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

June 01, 2023

Moderna to Present at Upcoming Conferences in June 2023

May 30, 2023

Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting

May 19, 2023

Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting

May 04, 2023

MODERNA AND NOVOCOL PHARMA ANNOUNCE FILL-FINISH AGREEMENT FOR CANADIAN-MADE MRNA VACCINES

May 04, 2023

Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates

May 03, 2023

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting

May 02, 2023

Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines

April 20, 2023

Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

April 20, 2023

Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science

April 16, 2023

Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA

April 11, 2023

Moderna Announces Clinical and Program Updates at 4th Vaccines Day

April 06, 2023

MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection

March 30, 2023

Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility